#covishield for 200

[news24fr]

Le Serum Institute of India s'emploie à commercialiser ses deux vaccins clés contre le Covid - Covovax et Covishield - en Chine, qui connaît une résurgence de la pandémie. "Il est très important pour le monde de revenir à ses problèmes de chaîne d'approvisionnement et d'investissement… (donc) il vaut mieux pour le monde que la Chine se remette de cela", a déclaré le chef du SII, Adar Ponawala, à NDTV dans une interview exclusive aujourd'hui. "Nous essayons de nous engager avec la Chine et de leur dire de mettre de côté les différences politiques, les problèmes et les appréhensions et de prendre certains des vaccins occidentaux comme rappel", a-t-il déclaré. Interrogé sur la réponse de la Chine, il a déclaré : "Je pense qu'ils décident de la direction qu'ils veulent prendre... J'espère juste qu'ils décideront rapidement d'une manière ou d'une autre". La nouvelle épidémie en Chine qui a commencé l'année dernière a été attribuée à un cocktail de virus par des experts indiens de la santé. Dans une interview avec NDTV l'année dernière, NK Arora, le chef du panel Covid du Centre, a déclaré: "En Chine, ils n'ont jamais été exposés au virus auparavant, et le vaccin qu'ils ont reçu est probablement moins efficace. La plupart d'entre eux ont reçu trois à quatre doses". M. Poonawalla a déclaré à NDTV que Covovax a fait ses preuves et fonctionne bien contre Omicron. Sa réponse est deux ou trois fois supérieure à celle même de Covishield – l'un des deux vaccins introduits pour la première fois en Inde et dans de nombreux autres pays. Le nouveau vaccin, a déclaré M. Poonawalla, coûtera environ 200 à 300 Rs et sera bientôt sur l'application CoWin du Centre. SII, a déclaré M. Poonawalla, a également soumis des données sur son vaccin contre le paludisme à l'Organisation mondiale de la santé. Le vaccin, a-t-il dit, s'est révélé efficace dans plus de 77% des cas et ils prévoient de le déployer d'ici la fin de l'année en Afrique. Le plus grand fabricant de vaccins en Inde, SII travaille également sur un vaccin contre la dengue, qui est en phase 2-3 d'essais cliniques. Le vaccin, à administrer en trois doses, pourra être prêt dans deux ans, a-t-il ajouté.

[clevercase]

'Trying to make everyone happy': Poonawalla says as SII rolls out first consignment of over 56L vaccine doses

‘Trying to make everyone happy’: Poonawalla says as SII rolls out first consignment of over 56L vaccine doses

Image Source : INDIA TV Serum Institute of India (SII) CEO Adar Poonawalla Pune-based Serum Institute of India (SII) on Tuesday rolled out the first consignment of over 56 lakh doses of Covishield vaccine for 13 cities across the country, four days ahead of a massive pan-India inoculation drive against COVID-19. Adar Poonawalla, Chief Executive Officer (CEO) of the institute, said various…

[everythingshouldbereality]

'Trying to make everyone happy': Poonawalla says as SII rolls out first consignment of over 56L vaccine doses

‘Trying to make everyone happy’: Poonawalla says as SII rolls out first consignment of over 56L vaccine doses

Image Source : INDIA TV Serum Institute of India (SII) CEO Adar Poonawalla Pune-based Serum Institute of India (SII) on Tuesday rolled out the first consignment of over 56 lakh doses of Covishield vaccine for 13 cities across the country, four days ahead of a massive pan-India inoculation drive against COVID-19. Adar Poonawalla, Chief Executive Officer (CEO) of the institute, said various…

[goedgekeurdcoronatest]

The COVID-19 Vaccine Countdown

Experts say that while the novel Coronavirus that hit planet earth in December 2019 created an unprecedented crisis for humankind the response to it by researchers, medical scientists and pharmaceutical companies in trying to discover a vaccine is also unprecedented. Under normal circumstances the process of discovering, testing and producing a vaccine takes from 5 years to 10 years thanks to the high failure rate associated with it. Therefore, the probability of having an effective COVID-19 vaccine within a year of the pandemic invasion is incredible news that speaks volumes about the non-stop efforts, dedication, round-the-clock supervision, utilization of special funds and global coordination put into it. As per the World Health Organization, at present there are nearly 200 vaccine candidates out of which 44 are in various stages of human clinical trials, and a few are about to be approved by the regulators. This would indeed be another crowing glory of the human quest should a safe and effective vaccine be really found and readied for public use in the coming months or even in the coming weeks. China had been the first casualty of the pandemic, and therefore the Chinese researchers went all out for a vaccine. Their vaccine, called CoronaVac, was in fact approved for emergency use within the country in August 2020 itself, of course, without completing the Phase-3 clinical trials. Phase-2 human trial results showed that the vaccine produced antibodies that could neutralize 10 strains of the SARS-CoV-2 virus without any severe adverse reactions. This vaccine could be out for distribution anytime. Russia became the first country to register a COVID-19 vaccine, Sputnik V, in August 2020 approving it for general use within the country, of course, without completing Phase-3 human trials. It has already claimed 92% efficacy, revised to 95% now. and the final trials are going on in several countries, Russia says the vaccine is being exported, including India. Another major vaccine being jointly developed and tested by the US pharmaceutical giant Pfizer and Germany's BioNTech is in the final clinical trials and it has claimed 95% efficacy based on interim data. The firms are likely to apply for emergency use authorization from the US regulators in mid-December 2020, and the vaccine could be out in the markets later next month subject to approval. Moderna, a vaccine by the US Pharma, is also in the final stages, and it has already claimed that it is 94.5% effective based on interim data. It is likely to apply for emergency use authorization a few days later than Pfizer-BioNTech. AstraZeneca, a vaccine developed by the Oxford University and co-developed by the Serum Institute of India (SII), has shown an average efficacy rate of 70% for Phase-3 trials with the likelihood of this going up to 90%. The vaccine has been proved to trigger an immune response in all age-groups, particularly and more significantly in the elderly group of below and above 70 years of age. The SII-developed vaccine Covishield is already priced at around USD 13 (1000 Rupees) per two doses, and the SII has been in the process of manufacturing 100 million doses within this year.  If you enjoyed this post and you would like to receive additional facts pertaining to overheid goedgekeurde coronatest kindly see our own website. Janssen, the pharmaceutical wing of Johnson and Johnson, is also developing a vaccine that is in the final human trials phase after a pause in October 2020 due to an illness in one of the participants. With both singe-dose and two-dose regimens the final trials of the vaccine are being conducted worldwide with participants up to 60,000, and interim data shows that the vaccine induced a robust immune response and had been well tolerated. Covaxin, a vaccine being developed by Bharat Biotech in India in collaboration with the Indian Council of Medical Research (ICMR), is also in the final phase clinical trials with the company saying that they expect at least a 60% efficacy rate in preventing the Coronavirus infection. Although the ICMR was hopeful of launching the vaccine by February 2021, Bharat Biotech sets a more practical launch date sometime in mid-2021. Normally, a regulator approves a vaccine if it is found to be at least 50% safe and effective, and therefore, there should not be any difficulty for all these final-stage vaccines to get the authorization or approval. However, experts the world over insist that Phase-3 trial results do not necessarily indicate a safe and effective vaccine, because it is not possible for a vaccine to account for all kinds of induced side-effects across humanity whatever be the size of its volunteers. They say that it is critical to monitor the safety and efficacy of a vaccine even long after its roll-out, and there can be no certainty, for even years. Prices and storage requirements of the rolled-out vaccines are among other concerns. Pfizer-BioNTech and Moderna are highly priced at USD 70 and USD 39 for the required two doses respectively. Besides, Pfizer-BioNTech requires storage at minus 70 degree Celsius while Moderna requires -19 C. Both of these factors make these vaccines difficult to obtain for the poor and developing countries. Hopefully, AstraZeneca, and its Indian counterpart Covishield, would be cheaper and it has been confirmed that it can be preserved in normal fridge temperatures. Sputnik V is also likely to be available at much lower prices, and Russians researchers have been engaged in testing a process of turning liquid Sputnik V into a dried white mass that can be stored at normal fridge temperatures of 2 C to 8 C and administered. This method is being termed as freeze-dried doses. Willingness of the citizens across the globe to go for COVID-19 vaccination is another factor to be considered. At the moment the figures reveal low levels of willingness. However, once a vaccine is proved to be safe and effective the willingness is bound to improve. Besides, the people in the medical and essential service sectors are always the priorities. With the second wave of the pandemic gripping several countries of the world we have no option but to hope for the best, that one of the vaccines that can arrive anytime eventually proves to be safe and effective in the long run.

[net4news]

Mumbai Mask Fine: BMC collects over Rs 60 crore in fines from people not wearing face masks in public | Mumbai News

MUMBAI: The Brihanmumbai Municipal Corporation (BMC) said on Friday that it has so far collected over Rs 60 crore as fines from people not wearing masks in public places since the outbreak of the Covid-19 pandemic. According to the civic body, a fine of Rs 60,48,34,400 was collected between April 2020 and July 2021. This amount is inclusive of the fines collected by the Mumbai Police and the Railways as well till July 15. The civic body had made it mandatory to wear masks in public places last year. Citizens who don’t follow face mask rules in public places are fined Rs 200 by the BMC. A fine of Rs 51,90,23,400 has been collected by the BMC, while the Mumbai Police has recovered a fine of Rs 8,07,71,800. A fine of Rs 50,39,200 has been collected from those travelling on Central, Western and Harbour railway lines. Meanwhile, immunization drives at government centres will operate till 5 pm on Friday. Citizens above 18 years of age can take the Covishield first and second dose, while healthcare workers and frontline workers can get the second dose of Covishield. Those beneficiaries above 45 years of age, can take the first and second dose of Covishield at drive-in centres. The BMC categorically mentioned that 50 per cent of doses will be given to people with online appointments, and 50 per cent is for on-spot registration. The second dose of Covishield vaccine will also be administered to those travelling from Mumbai to foreign countries for jobs and education or participating in Tokyo Olympics. BMC stated that the second dose will be given only if citizens have completed 28 days post first dose. They will need to carry the necessary documents like admission confirmation letters and I-20 or DS-160 forms for foreign visas. Also, on-spot registration will be done. The civic body has urged people to carry the certificate of the first dose. According to the BMC's health department, a total of 63,00,050 citizens have been inoculated against coronavirus in the metropolis till Thursday. Of these, 13,98,557 beneficiaries have received the second dose as well, the BMC said. Presently, Mumbai has 407 active COVID-19 vaccination centres - 286 of the BMC, 20 run by the Maharashtra government and 101 private centres. Source link Read the full article

[orbemnews]

India and Its Vaccine Maker Stumble Over Their Pandemic Promises NEW DELHI — Adar Poonawalla made big promises. The 40-year-old chief of the world’s largest vaccine maker pledged to take a leading role in the global effort to inoculate the poor against Covid-19. His India-based empire signed deals worth hundreds of millions of dollars to make and export doses to suffering countries. Those promises have fallen apart. India, engulfed in a coronavirus second wave, is laying claim to his vaccines. Other countries and aid groups are now racing to find scarce doses elsewhere. At home, politicians and the public have castigated Mr. Poonawalla and his company, the Serum Institute of India, for raising prices mid-pandemic. Serum has suffered production problems that have kept it from expanding output at a time when India needs every dose. He has come under criticism for departing to London amid the crisis, though he said it was only a quick trip. He told a British newspaper he had received threats from politicians and some of India’s “most powerful men,” demanding that he supply them with vaccines. When he returns to India, he will travel with government-assigned armed guards. In an interview with The New York Times, Mr. Poonawalla defended his company and its ambitions. He had no choice but to hand over vaccines to the government, he said. He cited a lack of raw materials, which he has partially blamed on the United States. Making vaccines, he said, is a painstaking process that requires investment and major risks. He said he would return to India when he had finished his business in London. He shrugged off his earlier comments about threats, saying they were “nothing we can’t handle.” But he also acknowledged that the Serum Institute alone doesn’t have the capacity to vaccinate India anytime soon, much less shoulder the burden of inoculating the world’s poor. “The problem is nobody took the risk that I did early on,” he said. “I wish that others did.” His position represents a dramatic turnabout for Serum and the Indian government. In January, when India launched its own vaccination program while also beginning exports, Prime Minister Narendra Modi pledged its vaccines would “save humanity.” Instead, the unfolding tragedy has made it clear that India — even with the world’s largest vaccine maker at its disposal — cannot save itself. India’s long-term vaccination prospects improved after the Biden administration on Wednesday backed waiving intellectual property protections for vaccines, which could make it easier for Indian factories to make them. Still, that won’t help India’s current crisis, which as of Friday had claimed more than 230,000 lives — a figure that likely represents a vast undercount. Serum won Mr. Modi’s favor in part because it fit the government’s narrative of a self-reliant India that was ready to take its place among the world’s major powers. Now both Mr. Modi’s government and Serum have been humbled, and their ambitions are being called into question. “Our capacity is extremely poor,” said Manoj Joshi, a fellow at the Observer Research Foundation in New Delhi, which focuses on Indian policymaking. “We are a poor country. I hope that we can build some humility into the system.” Mr. Poonawalla took the reins of the Serum Institute a decade ago from his father, Cyrus, a horse breeder turned vaccine billionaire. Before the crisis, he was extolled in the Indian media as an example of a new class of young, worldly entrepreneurs. Photos of him and his wife, Natasha, were a staple of fashion spreads. Last year, Serum struck a deal with AstraZeneca to produce a billion doses of its Oxford-AstraZeneca vaccine, called Covishield in India. Serum received a $300 million grant from the Gates Foundation to supply as many as 200 million doses of Covishield and another vaccine in development to the Gavi Alliance, the public-private partnership that is overseeing Covax, the program to donate vaccines to poor countries. Serum pledged between January and March to sell about 1.1 billion vaccine doses in coming months, according to a review of purchase agreements supplied by UNICEF. By the time India largely stopped vaccine exports, Serum had exported only about 60 million doses, about half to Gavi. India had claimed more than 120 million. Since then, AstraZeneca has served Serum a legal notice over delivery delays. Serum has just “temporarily deferred” its commitments, Mr. Poonawalla said, citing the Indian government’s halt of exports. “This is something coming from India,” he said. “It’s not the supplier that is defaulting.” The world is grappling with the ripple effect. A spokesman for Gavi said that India’s decision to prioritize “domestic needs” is having “a knock-on effect in other parts of the world that desperately need vaccines.” Still, in a sign of the lack of options for getting vaccines, Gavi on Thursday signed a purchase deal with an American vaccine company, called Novavax, involving doses to be made by Serum. Nepal, India’s northern neighbor, changed its procurement law to pay Serum an 80 percent advance, or roughly $6.4 million, to purchase two million doses of Covishield. Serum delivered the first million doses but is offering Nepal its money back for the second million, said Nepal’s health department director, Dr. Dipendra Raman Singh. Nepal has refused, in hope of getting more doses as India’s catastrophe bleeds across their border. Some of India’s needs are self-inflicted. It is manufacturing only two vaccines, Serum’s Covishield and one developed in India. A government deal to produce Russia’s Sputnik V in India has been tangled in red tape. If other manufacturers had started earlier, Mr. Poonawalla said, Serum might not face as much pressure. Serum’s failure to deliver is also AstraZeneca’s, since it pledged with Oxford University that the vaccine would be made available to countries that couldn’t afford it. “I felt very sad that we couldn’t continue helping them, but don’t forget my first priority comes to my nation first, which has given me everything,” Mr. Poonawalla said. “And after all, I am an Indian. I may be a global Indian company, but the fact is that we are in India. We need to take care of our own, like America has taken care of their own, Europe is taking care of their own.” But Serum can’t meet India’s needs, either. Serum’s plans were to split its doses 50-50 between India, either directly or through Covax, and the rest of the world. Now, Serum is contributing 90 percent of India’s supply and is still falling short. Less than 3 percent of the population has been fully inoculated. In some states, people are being turned away from vaccination centers that have run out of doses. Serum has missed its expansion targets. Mr. Poonawalla said last fall that by early this year, Serum Institute would be pumping out 100 million doses per month, of which about four in 10 would go overseas. But after a fire at a facility that was supposed to help the company ramp up vaccine production, Serum’s capacity has remained at about 72 million doses per month. A grant of more than $200 million from the Indian government should help the company reach its goal by summer, he said. Understand the Covid Crisis in India Mr. Poonawalla has also cited raw materials supplies. In April, he asked President Biden on Twitter to “lift the embargo” on raw material used to make Covid-19 vaccines. White House officials said Mr. Poonawalla mischaracterized his situation. Still, the United States said it would send raw materials to the Serum Institute to increase its vaccine production, though Mr. Poonawalla said they haven’t yet arrived. Mr. Poonawalla has also come under scrutiny for charging different prices to the central government, to India’s states and to private hospitals. Two weeks ago, Serum said it would charge state governments about $5 per dose, about $3 more than what it charges Mr. Modi’s government. Last week, following criticism, Mr. Poonawalla lowered the price to $4. Still, the critics point to an interview in which Mr. Poonawalla said that he was making a profit even at the central government’s price. Mr. Poonawalla said that Serum could sell at a lower price to India’s central government because it was ordering larger volumes. “People don’t understand,” Mr. Poonawalla told The New York Times. “They just take things in isolation and then they vilify you, not realizing that this commodity is sold at $20 a dose in the world and we’re providing it for $5 or $6 in India. There’s no end to the cribbing, the complaining, the criticizing.” Mr. Poonawalla has said he has received more than complaints. His company last month asked the Indian government to provide security for him, citing threats that the company hasn’t publicly disclosed. The government two weeks ago assigned him a detail that includes four to five armed personnel. In an interview with The Times of London newspaper published last week, he described receiving constant, aggressive calls demanding vaccines immediately. “‘Threats’ is an understatement,” he told the paper. He played down the threats in his interview with The New York Times, and his office declined to disclose further specifics. Still, the comments caused an uproar in India. Some politicians demanded that he name names. In a petition seeking extra security for Mr. Poonawalla in the Bombay High Court on Wednesday, Datta Mane, a Mumbai lawyer, said the vaccine tycoon had been threatened by chief ministers — India’s equivalent of governors — and business leaders. The company said it had no relationship with Mr. Mane and wasn’t involved with the petition. The Times of London reported that the threats had become so ominous that Mr. Poonawalla had fled India for Britain, a claim Mr. Poonawalla disputed. Instead, he said he was there on a business trip and to see his children, who started school there last year. His presence in London has only fueled his critics, who excoriated Serum’s price increases. Sunil Jain, the managing editor of The Financial Express newspaper, tweeted that Mr. Poonawalla’s departure to London was “shameful” and that he should reduce prices. The Serum Institute is planning a major expansion in Britain, investing nearly $335 million for research and development, to fund clinical trials, to build out its sales office and to possibly construct a manufacturing plant, Mr. Poonawalla’s office said. “Everyone is depending on us to be able to give this magic silver bullet in an almost infinite capacity,” Mr. Poonawalla said. “There’s this tremendous pressure from state governments, ministers, the public, friends, and they all want the vaccine. And I’m just trying to equitably distribute it as best I can.” Selam Gebrekidan in London and Bhadra Sharma in Kathmandu, Nepal, contributed reporting. Source link Orbem News #India #maker #Pandemic #Promises #Stumble #Vaccine

[freenewstoday]

New Post has been published on https://freenews.today/2021/04/25/u-s-to-give-india-raw-materials-for-vaccines-medical-supplies-to-help-fight-covid-surge/

U.S. to give India raw materials for vaccines, medical supplies to help fight Covid surge

Medical workers in personal cover protective equipment (PPE) stand alert mode outside the Covid-19 ward at Sir Ganga Ram Hospital on April 22, 2021 in New Delhi, India.

Sonu Mehta | Hindustan Times | Getty Images

WASHINGTON – The Biden administration said that it will immediately make raw materials needed for India’s coronavirus vaccine production available as the country works to counter the surge of Covid-19 infections.

In recent weeks, India has grappled with a staggering rise in new coronavirus infections. Over the weekend, India set another global record for daily cases, bringing the nation’s cumulative total to 16,960,172 cases, according to figures compiled by Johns Hopkins.

“Just as India sent assistance to the United States as our hospitals were strained early in the pandemic, the United States is determined to help India in its time of need,” National Security Council spokeswoman Emily Horne said in a statement on Sunday.

Horne added that the United States would send raw materials required for India to manufacture the Covishield vaccine, as well as therapeutics, rapid diagnostic test kits, ventilators and protective equipment.

“The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India, enabling BioE to ramp up to produce at least 1 billion doses of Covid-19 vaccines by the end of 2022,” Horne wrote, adding that the U.S. would also send a team of public health advisors from the Center for Disease Control and USAID to India.

The announcement comes on the heels of a Sunday call between Biden National Security Advisor Jake Sullivan and India’s National Security Advisor Ajit Doval. Sullivan “affirmed America’s solidarity with India, the two countries with the greatest number of Covid-19 cases in the world,” according to a readout of the call.

The U.S. response comes after Britain, France and Germany pledged aid to India over the weekend.

On Sunday, Biden wrote on Twitter that his administration was “determined to help India in its time of need.”

Last week, as the United States administered a new record of 200 million doses of the coronavirus vaccine, Biden told reporters that his administration was looking at more ways to help internationally.

“We’re looking at what is going to be done with some of the vaccines that we are not using. We’re going to make sure they are safe to be sent,” Biden said on April 21.

“We don’t have enough to be confident to send it abroad now.  But I expect we’re going to be able to do that,” he added.

Source

[roizcriteriodigital]

“No hay ninguna información”, reclaman médicos que desconocen cuándo serán vacunados contra covid-19

“En menos de una semana” se podría vacunar a todos los trabajadores sanitarios, pero el Minsa aún no completa ni las primeras 6000 vacunas

Cinthya Torrez

@cinthyabri

26 marzo, 2021

Trabajadores de la Salud del sector público y privado confirmaron a CONFIDENCIAL que desconocen cuándo y cómo el Ministerio de Salud (Minsa) iniciará a inmunizarlos contra la covid-19, pese a que desde hace una semana, cuenta con 335 000 dosis de vacunas: 200 000 Covishield, donadas por el Gobierno de India y 135 000 canalizadas a través del Mecanismo Covax de la Organización Panamericana de la Salud (OPS). Además de un lote de vacunas Sputnik V, que son las únicas que en este momento está administrando.

Dosis de vacuna Covishield se administrarán luego de Semana Santa

La vicepresidenta y vocera del régimen, Rosario Murillo, aseguró el martes que aún falta completar la primera dosis de vacuna Sputnik V a pacientes del programa de Insuficiencia Renal Crónica; “son ya muy pocas-personas-“, expresó, pero no especificó, cuántos de los 3 000 programados, ya han sido inmunizados.LEER MAS https://www.confidencial.com.ni/nacion/personal-sanitario-desconoce-cuando-sera-vacunado-contra-la-covid-19-por-el-minsa/

[cearahoje]

Pfizer vai entregar 14 milhões de doses de vacina para o Brasil até junho

O governo federal informou hoje (8) que a farmacêutica norte-americana Pfizer vai entregar ao Brasil 14 milhões de doses da sua vacina contra covid-19 até junho deste ano. O presidente Jair Bolsonaro se reuniu com o presidente da Pfizer, Albert Bourla, nesta segunda-feira, por videoconferência, e pediu a antecipação de lotes do imunizante, que foi desenvolvido em parceria com empresa de biotecnologia alemã BioNtech.

(Foto: Reprodução/ Pfizer)

Após o encontro, o assessor especial do Ministério da Saúde, Airton Soligo, explicou que o contrato com a farmacêutica previa a entrega 99 milhões de doses este ano, sendo 2 milhões em maio, 7 milhões em junho e o restante no segundo semestre. Segundo ele, a Pfizer se comprometeu a antecipar 5 milhões de doses, a serem entregues entre maio e junho – totalizando 14 milhões de doses no primeiro semestre.

Além disso, a entrega de cerca de 60 milhões de doses da vacina estava concentrada no último trimestre do ano, mas, de acordo com Soligo, também haverá um esforço para antecipar esses lotes para o terceiro trimestre. A vacina da Pfizer teve seu registro definitivo aprovado pela Agência Nacional de Vigilância Sanitária (Anvisa) no mês passado.

O presidente Jair Bolsonaro também vai se reunir com representante da Janssen (braço da empresa Johnson & Johnson) para tratar da aquisição de 30 milhões de doses de vacina contra covid-19.

De acordo com Soligo, estados e municípios já receberam 20 milhões de doses para a vacinação da população contra a doença que já matou mais de 265,4 mil pessoas no país.

São vacinas aprovadas no Brasil para uso emergencial: a CoronaVac, produzida pelo Instituto Butantan em parceria com a farmacêutica chinesa Sinovac, e a vacina Covishield, produzida pela Fundação Oswaldo Cruz (Fiocruz) em parceria com a Universidade de Oxford e o laboratório inglês AstraZeneca.

Até o final de março, segundo o assessor, mais 31,8 milhões de doses estarão disponíveis: 25 milhões da Coronavac e 6,8 milhões da Covishield. No caso da vacina AstraZeneca/Oxford serão 3,8 milhões produzidas pela Fiocruz e 3 milhões produzidas na Coreia do Sul e entregues pela iniciativa Covax, da Organização Mundial da Saúde (OMS). Em abril, a previsão é de mais 42 milhões de doses de vacinas, sem contar os imunizantes Covaxin e Sputnik V que também estão sendo negociados pelo governo federal.

“A partir de agora, o Brasil, nos próximos 60 dias, aplicará 1 milhão de doses [diárias] e, a partir de maio, passa a ser no mínimo de 1,5 milhão de doses por dia”, disse Soligo em entrevista à imprensa após a reunião no Palácio do Planalto. “A Fiocruz já está produzindo 400 mil doses por dia formará um lote grande; o Butantan, 660 mil doses por dia. Ou seja, o Brasil apostou certo quando apostou na AstraZeneca e no próprio Butantan”, completou.

Negociações

De acordo com o ministro da Economia, Paulo Guedes, a antecipação da entrega de vacinas pela Pfizer foi possível pois a farmacêutica aumentou a sua capacidade de produção de 1,5 milhão para 5 milhões de doses diárias. “E fazendo isso deve haver mais vacina para todo mundo, inclusive para nós”, disse em entrevista à imprensa no Palácio do Planalto, ao lado de Soligo.

As negociações para aquisição de imunizantes com a Pfizer e a Janssen aconteceram depois da aprovação de um projeto de lei que facilitou a compra de vacinas com autorização para uso em caráter emergencial pela Agência Nacional de Vigilância Sanitária (Anvisa) por estados, municípios e por empresas. No caso do setor privado, as doses devem ser integralmente doadas ao Sistema Único de Saúde (SUS) enquanto o público prioritário não tiver sido vacinado.

O texto também permite que estados, Distrito Federal e municípios assumam a responsabilidade civil por eventuais efeitos adversos provocados pelos imunizantes, desde que estes tenham obtido registro na Anvisa. Essa é uma exigência feita pela Pfizer/BioNTech e Janssen. A ausência de responsabilização ao laboratório em caso de atraso na entrega ou de eventuais efeitos colaterais do imunizante, entre outras condições, causaram entraves na negociação entre governo e Pfizer.

“Cada um tenta fazer na sua área o melhor possível para o Brasil. E, claramente, nessa negociação anterior com a Pfizer, o problema de escala foi um problema sério. Não fazia sentido 100 mil ou 200 mil doses para um país como o Brasil. Então, o Brasil o tempo inteiro pedindo [fabricação em] escala e eles, por sua vez, pedindo exigências, que, dos dois lados, demoraram um pouco na negociação”, disse Guedes.

Fonte: Agência Brasil

O post Pfizer vai entregar 14 milhões de doses de vacina para o Brasil até junho apareceu primeiro em O Estado CE.

The post Pfizer vai entregar 14 milhões de doses de vacina para o Brasil até junho first appeared on Ceará Hoje.

from WordPress https://ift.tt/2PC8RLK via IFTTT

[toprenders]

The COVID-19 Vaccine Countdown!

Experts say that while the novel Coronavirus that hit planet earth in December 2019 created an unprecedented crisis for humankind the response to it by researchers, medical scientists and pharmaceutical companies in trying to discover a vaccine is also unprecedented. Under normal circumstances the process of discovering, testing and producing a vaccine takes from 5 years to 10 years thanks to the high failure rate associated with it. Therefore, the probability of having an effective COVID-19 vaccine within a year of the pandemic invasion is incredible news that speaks volumes about the non-stop efforts, dedication, round-the-clock supervision, utilization of special funds and global coordination put into it. As per the World Health Organization, at present there are nearly 200 vaccine candidates out of which 44 are in various stages of human clinical trials, and a few are about to be approved by the regulators. This would indeed be another crowing glory of the human quest should a safe and effective vaccine be really found and readied for public use in the coming months or even in the coming weeks.

China had been the first casualty of the pandemic, and therefore the Chinese researchers went all out for a vaccine. Their vaccine, called CoronaVac, was in fact approved for emergency use within the country in August 2020 itself, of course, without completing the Phase-3 clinical trials. Phase-2 human trial results showed that the vaccine produced antibodies that could neutralize 10 strains of the SARS-CoV-2 virus without any severe adverse reactions. This vaccine could be out for distribution anytime.

Russia became the first country to register a COVID-19 vaccine, Sputnik V, in August 2020 approving it for general use within the country, of course, without completing Phase-3 human trials. It has already claimed 92% efficacy, revised to 95% now. and the final trials are going on in several countries, Russia says the vaccine is being exported.

Another major vaccine being jointly developed and tested by the US pharmaceutical giant Pfizer and Germany's BioNTech is in the final clinical trials and it has claimed 95% efficacy based on interim data. The firms are likely to apply for emergency use authorization from the US regulators in mid-December 2020, and the vaccine could be out in the markets later next month subject to approval.

Moderna, a vaccine by the US Pharma, is also in the final stages, and it has already claimed that it is 94.5% effective based on interim data. It is likely to apply for emergency use authorization a few days later than Pfizer-BioNTech. AstraZeneca, a vaccine developed by the Oxford University and co-developed by the Serum Institute of India (SII), has shown an average efficacy rate of 70% for Phase-3 trials with the likelihood of this going up to 90%. The vaccine has been proved to trigger an immune response in all age-groups, particularly and more significantly in the elderly group of below and above 70 years of age. The SII-developed vaccine Covishield is already priced at around USD 13 (1000 Rupees) per two doses, and the SII has been in the process of manufacturing 100 million doses within this year.

Janssen, the pharmaceutical wing of Johnson and Johnson, is also developing a vaccine that is in the final human trials phase after a pause in October 2020 due to an illness in one of the participants. With both singe-dose and two-dose regimens the final trials of the vaccine are being conducted worldwide with participants up to 60,000, and interim data shows that the vaccine induced a robust immune response and had been well tolerated. Normally, a regulator approves a vaccine if it is found to be at least 50% safe and effective, and therefore, there should not be any difficulty for all these final-stage vaccines to get the authorization or approval. However, experts the world over insist that Phase-3 trial results do not necessarily indicate a safe and effective vaccine, because it is not possible for a vaccine to account for all kinds of induced side-effects across humanity whatever be the size of its volunteers. They say that it is critical to monitor the safety and efficacy of a vaccine even long after its roll-out, and there can be no certainty, for even years.  COVID testing ABD treatment

Prices and storage requirements of the rolled-out vaccines are among other concerns. Pfizer-BioNTech and Moderna are highly priced at USD 70 and USD 39 for the required two doses respectively. Besides, Pfizer-BioNTech requires storage at minus 70 degree Celsius while Moderna requires -19 C.

Willingness of the citizens across the globe to go for COVID-19 vaccination is another factor to be considered. At the moment the figures reveal low levels of willingness. However, once a vaccine is proved to be safe and effective the willingness is bound to improve. Besides, the people in the medical and essential service sectors are always the priorities. With the second wave of the pandemic gripping several countries of the world we have no option but to hope for the best, that one of the vaccines that can arrive anytime eventually proves to be safe and effective in the long run.

[notisur]

India donará 200 mil dosis de la vacuna Covishield de AstraZeneca

India donará 200 mil dosis de la vacuna Covishield de AstraZeneca

Según el presidente Alejandro Giammattei, se acercaron al gobierno de la India en busca de información para la compra, pero en lugar de ello obtuvieron una oferta de donación. La vacuna Covishield está siendo desarrollada en el Instituto Serum de la India, en colaboración en colaboración con la Universidad de Oxford y AstraZeneca.

[craftyeaglebeard]

印度啟動疫苗出口，對像是“友好國家”

 從1月20日起，印度政府正式開始對外出口新冠肺炎疫苗，不丹、馬爾代夫、孟加拉國將成為首批獲得印度產疫苗的國家。印度媒體在報導中強調，印度疫苗將優先發往“友好國家”。

《印度斯坦時報》援引知情人士的話說，20日當天，將有15萬劑印度血清研究所與英國牛津大學和阿斯利康公司聯合研發的Covishield疫苗被發往不丹，10萬劑發往馬爾代夫，上述國家一線醫療工作者和老年人可能是率先接種疫苗的人群。孟加拉國也將於21日派遣專機從印度運回此前訂購的200萬劑疫苗。匿名消息人士對《環球時報》記者表示，尼泊爾、緬甸、塞舌爾、斯里蘭卡、阿富汗、毛里求斯也是印度疫苗主要出口目的地，目標是“計劃向友好國家提供至少1000萬劑疫苗”，“後續將繼續視情況擴大疫苗出口的規模”。日本藤素 必利吉 岡本藥妝店 美國maxman增大丸 犀利士 雙效犀利士 紅金偉哥 

 日本藤素  Japan tengsu 日本藤素沒用  日本藤素副作用  日本藤素官網  日本藤素ptt  日本藤素官網總代理  日本藤素授權臺灣代理有限公司  日本藤素功效  日本藤素價格  日本藤素吃法  日本藤素正品藥片顏色

彭博社20日報導稱，印度疫苗的產量未來有望增加到每月5億劑，其良好的性價比也吸引了英國、比利時、中東和非洲國家的目光。知情人士表示，南非、肯尼亞和尼日利亞等非洲國家正在與印度就疫苗出口進行談判。印度總理莫迪此前曾向巴西領導人親自允諾向該國出口疫苗，因此預計巴西也將“榜上有名”。目前，印度早期階段出口的疫苗大部分以援贈方式為主，且全部為Covishield疫苗。另一家獲得國內緊急使用授權的印度巴拉特生物技術公司研發的Covaxin疫苗暫不在出口名單之列。根據印度衛生部門發布的數據，截至20日，印度全國共有約67.48萬人完成接種，其中出現不良反應的有數百人，需住院觀察的有9人。

印度流行病學專家桑吉·庫馬爾對《環球時報》記者表示，印度疫苗出口面臨的最大問題並非來自疫苗本身，而是印度的疫苗生產能力能否滿足國內和國際的雙重需求。作為一個擁有13億多人口的大國，印度需要在滿足國內接種目標的同時，為多個國家提供疫苗，而目前僅有血清研究所一家生產出口疫苗，“這是否能支撐莫迪此前提出的'印度將在未來數月內成為全球疫苗主要供應國'的雄心？”此外，匿名行業人士對記者說，印度疫苗的現行官價為200盧比（約合人民幣17.7元）/劑，但疑似流入黑市疫苗價格已炒至1000盧比，如何控制疫苗市場也是印度政府需要考慮的問題。▲

[darshan-bioinformatics]

COVISHIELD VACCINE

                                     COVISHIELD VACCINE

COVID-19 disease is caused by a coronavirus called SARS-CoV-2. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory illness that can affect other organs. Covishield, along with Bharat Biotech’s Covaxin, were approved for restricted emergency use by the Drugs Controller General of India (DGCI) on January 3 (Sunday). Covishield is manufactured and marketed by Serum Institute of India in Pune. Covishield is developed by Oxford-AstraZeneca in collaboration with Serum Institute of India,Pune.

Covishield vaccine includes the following ingredients: L-Histidine, L-Histidine hydrochloride monohydrate, Magnesium chloride hexahydrate, Polysorbate 80, Ethanol, Sucrose, Sodium chloride, Disodium edetate dihydrate (EDTA), Water for injection. The AstraZeneca (COVISHIELD) COVID-19 (AZD1222) coronavirus vaccine candidate, formerly known as ChAdOx1 nCoV-19, is made from a virus (ChAdOx1), a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees, that has been genetically changed so that it can't grow in humans.

Genetic material has been added to the ChAdOx1 construct, which is used to make proteins from the SARS-CoV-2 coronavirus called Spike glycoprotein (S). This protein is usually found on the surface of SARS-CoV-2 and plays an essential role in the infection pathway of the SARS-CoV-2 virus.The SARS-CoV-2 coronavirus uses its spike protein to bind to ACE2 receptors on human cells to enter the cells and cause an infection. After vaccination, the surface spike protein is produced, priming the immune system to attack the coronavirus if it later infects the body and causes COVID-19 disease

By vaccinating with AZD1222 (ChAdOx1 nCoV-19), these researchers hope to make the body recognize and develop an immune response to the Spike protein to help stop the SARS-CoV-2 virus from entering human cells and therefore prevent infection. The dose will be given to an individual as an intramuscular (IM) injection, ideally on the deltoid muscle and the vaccination course comprises two separate doses of 0.5 millilitres (ml) each, according to SII. If you receive one dose of the Covishield vaccine, then the second dose should be administered between 4 to 6 weeks after the first dose. The first 100 million doses of the vaccine has been provided to the government at the cost of ₹200 per dose, with SII’s chief executive officer (CEO) and owner Adar Poonawalla adding that the cost will increase later on.

Prime Minister Narendra Modi launched India’s Covid-19 vaccination drive, the world’s largest inoculation exercise against the novel coronavirus on 16th of January,2021. As India began its nationwide vaccination drive against Covid-19, as many as 1,65,714 people were vaccinated on Day 1, Union Health Ministry said.

References:

https://www.news18.com/news/buzz/how-oxford-scientists-developed-astrazenecas-covishield-vaccine-in-record-time-3291593.html

https://www.nature.com/articles/s41586-020-2608-y

https://www.livemint.com/science/health/covid19-an-faq-factsheet-for-covishield-vaccine-by-serum-institute-11610496726579.html

[amadisalcaraz]

Comienza vacunación en Hospital San Juan de Dios

La tarde de este jueves 25 de Febrero se comenzó con el proceso de vacunación contra COVID-19 a personal médico de esta instalación de salud. El primer vacunado fue el Dr. Enrique Pérez de 52 años, jefe de la emergencia fue el primer médico en ser vacunado.

En el hospital General San Juan de Dios también dio inicio la vacunación contra #COVID19, el Dr. Enrique Pérez de 52 años, jefe de la emergencia fue el primer médico en ser vacunado. pic.twitter.com/XTdGzzoEnv

— Ministerio de Salud Pública (@MinSaludGuate) February 26, 2021

La India dona 200 mil dosis contra COVID-19

El Presidente de la República agradeció al Gobierno de la India por su generosa donación de 200 mil dosis de la vacuna contra COVID-19 que arribarán al país el próximo martes por la noche.

Durante una ceremonia, este viernes 26 de Febrero se dio a conocer la noticia y que para finales de año tendremos a 7 millones de guatemaltecos vacunados.

Agradezco a @PMOIndia, @narendramodi, por la generosa donación de 200 mil dosis de vacunas #Covishield que nos ayudarán a salvar vidas e inmunizar al personal sanitario de primera línea.

#VacunasCovidGT pic.twitter.com/bLUggtWEuy

— Alejandro Giammattei (@DrGiammattei) February 26, 2021

Desmienten reacciones por vacuna contra COVID-19

Mediante redes sociales se dio a conocer el rumor sobre supuestas reacciones que tuvo la enfermera Magdalena Guevara González después de recibir la dosis contra COVID-19.

El Ministerio de Salud explicó que los receptores de la vacuna siguen un protocolo de observación para descartar cualquier reacción o problema que pudieran tener los receptores.

ATENCIÓN

Luego de la vacunación, el personal permanece en observación por unos minutos como parte del protocolo. Lamentamos esta falta de respeto hacia la salud, dignidad humana e intimidad del personal de salud. No difundas rumores, infórmate por fuentes oficiales. pic.twitter.com/OYiTqr1Bfs

— Ministerio de Salud Pública (@MinSaludGuate) February 26, 2021

Rendirán honores a General de brigada

En las instalaciones de la Fuerza Aérea Guatemalteca del #EjércitoGT | #MINDEF, se realiza valla a los restos del General de Brigada Pablo Nuila Hub #Kaibil001 que serán trasladados hacia la Brigada de Fuerzas Especiales en Poptún, #Petén, para sus respectivos honores.

En las instalaciones de la Fuerza Aérea Guatemalteca del #EjércitoGT | #MINDEF, se realiza valla a los restos del General de Brigada Pablo Nuila Hub, #Kaibil001, que serán trasladados hacia la Brigada de Fuerzas Especiales en Poptún, #Petén, para sus respectivos honores. pic.twitter.com/8HjSfUFyv1

— Ejército Guatemala (@Ejercito_GT) February 26, 2021

Entregan la Orden Nacional del Patrimonio Cultural

El viernes 26 de Febrero, el Ministerio de Gobernación reconoce a aquellos guatemaltecos ilustres que conservan y salvaguardan nuestra memoria histórica y apoyan a la construcción del proyecto de nación, que nos permite reconocer a los guatemaltecos y al mundo que somos un país excepcional.

Los seis galardonados fueron Miguel Orrego, Christa Schieber, Ana María Urruela, Ramiro Irungaray, Rudy Cotton y José Luis Colmenares.

Es un verdadero honor para mí entregar la Orden Nacional del Patrimonio Cultural de Guatemala a seis distinguidos guatemaltecos: Miguel Orrego, Christa Schieber, Ana María Urruela, Ramiro Irungaray, Rudy Cotton y José Luis Colmenares. pic.twitter.com/ifDDH3klZn

— Alejandro Giammattei (@DrGiammattei) February 26, 2021

El Ministerio de Comunicaciones promueve la reactivación económica

El Ministro de Comunicaciones, Josué Lémus, dio el banderazo de inicio a los trabajos de reposición de asfalto del tramo carretero del Monumento a La Marimba hacia la Avenida Las Américas en Quetzaltenango.

De esta manera se beneficia a los pobladores y visitantes con un mejor acceso a lugares turísticos y emblemáticos de Quetzaltenango.

¡En el #CIV contribuimos a la reactivación económica del país! Hoy el Ministro de Comunicaciones Ing. #JosuéLémus da el banderazo de inicio a los trabajos de reposición de asfalto del tramo carretero del Monumento a La Marimba hacia la Avenida Las Américas en #Quetzaltenango. pic.twitter.com/FJoxwbM8jm

— Ministerio de Comunicaciones (@CIVguate) February 26, 2021

El cargo Comienza vacunación en Hospital San Juan de Dios apareció primero en Bien Mi Guate.

source https://bienmiguate.com/vacunacion-hospital-san-juan-de-dios/ Comienza vacunación en Hospital San Juan de Dios posted first on https://bienmiguate.com/ from Amadis Alcaraz https://amadisalcaraz.blogspot.com/2021/02/comienza-vacunacion-en-hospital-san.html